Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study.

Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. Abstract Text:

    donald w blackDonald W Black,stephan arndtStephan Arndt,william h coryellWilliam H Coryell,tami argoTami Argo,kelsie t forbushKelsie T Forbush,martha c shawMartha C Shaw,paul perryPaul Perry,jeff allenJeff Allen,

    We tested the efficacy of bupropion in the treatment of persons with pathological gambling (PG). Nondepressed, healthy subjects with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition PG were randomly assigned to placebo or flexibly dosed bupropion in a 12-week double-blind trial. Outcome measures included the Yale-Brown Obsessive-Compulsive Scale modified for PG, the Gambling Severity Assessment Scale, the Clinical Global Impression Improvement and Severity Scales, the Global Assessment Scale, the Timeline Follow Back, the Attention-Deficit/Hyperactivity Disorder Rating Scale, and the Sheehan Disability Scale. Thirty-nine subjects (28 men, 11 women) were randomized to bupropion (n = 18) or placebo (n = 21). The 2 groups were similar on demographic and clinical measures. There were few differences between the treatment groups on any primary or secondary outcome measure, although subjects in each cell experienced significant improvement. Of subjects with at least 1 postrandomization visit, 35.7% of bupropion and 47.1% of placebo recipients experienced "much" or "very much" improvement on the Clinical Global Impression Improvement Scale. The trial was complicated by a high noncompletion rate (43.6%). Bupropion was well tolerated. Bupropion and placebo recipients did equally well in a short-term trial, with improvement seen as early as the first week of treatment. The high placebo response rate and the high noncompletion rate each reflect the challenge inherent in treating persons with PG.

    Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. Publishing Authors By Initials

    dw blackDW Black,s arndtS Arndt,wh coryellWH Coryell,t argoT Argo,kt forbushKT Forbush,mc shawMC Shaw,p perryP Perry,j allenJ Allen,

    For similar stomatognathic diseases: mouth diseases: salivary gland diseases: xerostomia research abstracts see: stomatognathic diseases: mouth diseases: salivary gland diseases: xerostomia research

    PUBMED ID PMID:

    MEDLINE DATE:

    Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. Journal Published:

    PUBLICATION TYPE: Research Support, N.I.H., Extr

    Journal: Journal of clinical psychopharmacology

    VOLUME: 27

    Page Numbers: 143-50

    Journal Abbreviation:

    ISSN: 0271-0749

    DAY: 3

    MONTH: Apr

    YEAR: 2007

    Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8109496

    Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. Keywords Mesh Terms:

    KEYWORDS: Xerostomia

    MESH TERMS: chemically induced

    Chemical & Substance for Abstract: Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. Information

    Substance Name: Bupropion

    Registry Number: 34841-39-9

    Grant and Affiliation Information for Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study.

    AFFILIATION: Department of Psychiatry, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA 52242, USA. donald-black@uiowa.edu

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY: United States NIMH

    GRANT: R21 MH-063289

    ACRONYM: MH

    MEDLINETA: J Clin Psychopharmacol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News